Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer
- 375 Downloads
To investigate feasibility, safety, and efficacy of salvage radical prostatectomy (RP) for recurrent prostate cancer (PCa) after focal treatment with TOOKAD® Soluble vascular-targeted photodynamic therapy (VTP).
Nineteen patients underwent RP after biopsy-proven PCa post-focal VTP. We reported: operation time, blood loss, transfusion, complications, urethral catheterization time, functional outcomes, and short-term oncologic outcomes.
Median age was 64 years (58–70). Median PSA before VTP was 6.30 ng/ml (3.20–9.80). Median delay between VTP and RP was 17 months (8–48). Median blood loss was 400 ml (100–1,000). Median operation time was 150 min (90–210), median urethral catheterization time was 7 days (5–18), and median hospital stay was 7 days (4–21). There was no perioperative mortality. Three patients had related per-operative complications: one pelvic hematoma (150 cc) (Clavien IIIa), one per-operative transfusion (900 cc hemorrhage) (Clavien II), and one superficial wound infection (Clavien I). After a median follow-up of 10 months (1–46), 13 were completely continent (68 %), five needed ≤1 pad/day, and one needed 3 pads/day (Clavien I). Severe erectile dysfunction was observed before and after RP (respectively 8 and 18). Ten patients regained potency with appropriate treatment. Median postoperative PSA was 0.02 ng/ml (<0.01–0.38) and remained undetectable for 16 patients (84 %). Nine patients had positive margins and six underwent complementary radiotherapy. Positive margins were significantly associated with bilateral VTP [risk ratio = 4.3, 95 % confidence interval (1.6–11.7), p = 0.003].
Salvage RP after VTP treatment was feasible, safe, and efficient to treat most of the locally recurrent PCa. Short-term oncologic and functional outcomes were promising, but further studies are required.
KeywordsSalvage therapy Radical prostatectomy Prostate cancer Focal therapy WST11 TOOKAD® Soluble Vascular-targeted photodynamic therapy
We thank Pr Guy, Pr Bouchot, Dr. Barré, Dr. Navara, and Dr. Mandron for their collaboration.
Conflict of interest
Pr Azzouzi is investigator and proctor for Steba Biotech. Pr Villers is lecturer for Steba Biotech. All other authors have no conflict of interest related to this study.
Ethical and regulatory approvals were sought and obtained from the relevant national and local authorities.
- 1.Ferlay JS-FE, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2012) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013:1374–1403Google Scholar
- 7.Eymerit-Morin C, Zidane M, Lebdai S, Triau S, Azzouzi AR, Rousselet MC (2013) Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer. Virchows Arch 463(4):547–552Google Scholar
- 8.Moore CM, Azzouzi AR, Barret E et al (2014) Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localized prostate cancer using WST11-Vascular Targeted Photodynamic (VTP) therapy. BJU Int. doi: 10.1111/bju.12816
- 9.Heidenreich A, Bellmunt J, Bolla M, Joniau S et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 65(1):124–137Google Scholar